Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002818 · ClinicalTrials.gov registry record · Phase 1

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

A Phase 1 study, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT00002818: Completed Phase 1 study, sponsored by Virginia Commonwealth University.

NCT00002818 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002818, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Deoxycytidine may protect patients from the side effects of high-dose cytarabine. PURPOSE: Phase I trial to study the effectiveness of high-dose cytarabine given with deoxycytidine in treating patients who have refractory acute myelogenous leukemia or other lymphoma or leukemia.

Interventions

  • DRUG deoxycytidine
  • DRUG cytarabine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 1995-02
Est. Completion 2001-02
Phase Phase 1
Virginia Commonwealth University

558 total trials

What the finished NCT00002818 record still lists

NCT00002818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 2 interventions - of which deoxycytidine is the first listed.

NCT00002818 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002818 about?

NCT00002818 is a clinical study titled "High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Deoxycytidine may protect patients from the side effects of high-dose cytarabine. PURPOSE: Phase I trial to study the effectiveness of high-dose cytarabine given with deoxycytidi...

What is the current status of trial NCT00002818?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1995-02. Estimated completion is 2001-02.

What interventions are being tested in trial NCT00002818?

The interventions under investigation include: deoxycytidine (DRUG), cytarabine (DRUG).

Who is sponsoring clinical trial NCT00002818?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00002818's enrollment target sits among peer trials

15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002818, the US trial registry maintained by the National Library of Medicine. NCT00002818 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.